EUVIMEDEUVIMED entdecken
Crossref

Research progress of sorafenib in tumor therapy

Huijie Zhang, Weidong Guo

Discussion of Clinical Cases · 2015

DOI: 10.14725/dcc.v2n3p41 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Discussion of Clinical Cases, 2015. Verfasst von Huijie Zhang und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multi-kinase inhibitor Sola Fini (sorafenib), as the first approved multi-target agent, is a noval multi-target signal transduction inhibitors, which can inhibit the proliferation of tumor cells, prevent tumor angiogenesis and induce apoptosis of tumor cells. Studies have shown that Sola Fini imposes extensive antitumor activity on animal model of human tumor xenograft, such as mouse renal cell carcinoma, colon cancer, pancreatic cancer, thyroid cancer, non-small cell lung cancer, breast cancer and ovarian cancer model. In this paper, the mechanism of anti-tumor of sorafenib and the progress of tumor therapy are reviewed.

Zitieren

APA

Zhang, H., & Guo, W. (2015). Research progress of sorafenib in tumor therapy. Discussion of Clinical Cases. https://doi.org/10.14725/dcc.v2n3p41

Vancouver

Zhang H, Guo W. Research progress of sorafenib in tumor therapy. Discussion of Clinical Cases. 2015. doi:10.14725/dcc.v2n3p41

BibTeX
@article{Zhang2015,
  author = {Zhang, Huijie and Guo, Weidong},
  title = {Research progress of sorafenib in tumor therapy},
  journal = {Discussion of Clinical Cases},
  year = {2015},
  doi = {10.14725/dcc.v2n3p41}
}
Kostenlos starten →